Suggested remit: To appraise the clinical and cost effectiveness of Itulazax 12 standardised quality pollen from white birch (betula verrucosa) sublingual lyophilisate immunotherapy (12 SQ-Bet SLIT) within its marketing authorisation for treating moderate to severe allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6462

Provisional Schedule

Committee meeting: 1 02 July 2025
Expected publication 11 September 2025

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Alk-Abelló (Itulazax)
Others Department of Health and Social Care
  NHS England
Patient carer groups Allergy UK
  Anaphylaxis UK
  Asthma Relief Charity
  Asthma + Lung UK
  Fifth Sense
  NARA – The Breathing Charity
  South Asian Health Foundation
  Specialised Healthcare Alliance
  The Samter’s Society
Professional groups Association for Respiratory Technology and Physiology
  Association of Respiratory Nurse Specialists
  British Geriatrics Society
  British Paediatric Respiratory Society
  British Society for Allergy & Clinical Immunology
  British Society for Immunology – Clinical Immunology Professional Network
  British Thoracic Society
  ENT UK
  National Heart and Lung Institute
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Allergy Therapeutics UK (Pollinex Grass)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Asthma, Allergy and Inflammation Research Trust
  British Association for Lung Research
  Cochrane Airways Group
  David Hide Asthma and Allergy Research Centre
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
12 December 2024 Referral
12 December 2024 Referral
12 December 2024 Referral
12 December 2024 Referral
19 November 2024 Invitation to participate
18 September 2024 - 16 October 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6462
18 September 2024 In progress. Scoping commencing
25 July 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
20 June 2024 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual